Company intelligence / Profile preview

SparingVision

Ownership: Private
Employees: ~40
Development stage: Phase 1

Overview

SPVN06 has completed Phase I and received positive DSMB recommendation to advance to Phase II in the PRODYGY trial as of January 2025. The company is developing mutation-agnostic gene therapies for retinal diseases.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyGenome editing (CRISPR/Cas9)
Industry: Biotech

Drug pipeline

7 assets

SPVN06

6 more assets in the full pipeline.

Partnerships

Intellia Therapeutics

Beyond the preview

Go deeper on SparingVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SparingVision.